In 2004, the FDA approved another low molecular mass quinazolinamine EGFR tyrosine kinase inhibitor, erlotinib (Tarceva), as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC, for whom chemotherapy treatment was ineffective [86] (Figure 4b, Table 1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.